Evaluation of recombinant hirudin (CGP 39 393/TM REVASC) in the prevention of restenosis after percutaneous transluminal coronary angioplasty: Rationale and design of the HELVETICA trial, a multicentre randomized double blind heparin controlled study

Herrman, J.-P. R.; Simon, R.; Umans, V. A. W. M.; Peerboom, P. F.; Keane, D.; Rijnierse, J. J. M. M.; Bach, D.; Kobi, P.; Kerry, R.; Close, P.; Deckers, J. W.; Serruys, P. W.

期刊名称European Heart Journal
作者Herrman, J.-P. R.; Simon, R.; Umans, V. A. W. M.; Peerboom, P. F.; Keane, D.; Rijnierse, J. J. M. M.; Bach, D.; Kobi, P.; Kerry, R.; Close, P.; Deckers, J. W.; Serruys, P. W.
卷第16卷
印刷ISSN0195-668X
电子ISSN1522-9645
文件大小680.48KB
发表时间1995-11-02
DOI10.1093/eurheartj/16.suppl_l.56
页码56-62

发现好书期刊，享受阅读乐趣

Evaluation of recombinant hirudin (CGP 39 393/TM REVASC) in the prevention of restenosis after percutaneous transluminal coronary angioplasty: Rationale and design of the HELVETICA trial, a multicentre randomized double blind heparin controlled study